Evidence map›Paper›PMID 34581850›Full record

ArticleVirchows Archiv : an international journal of pathology2022

Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status.

Shiho Asaka, Tomoyuki Nakajima, Koichi Ida, Ryoichi Asaka, Chinatsu Kobayashi, Masayuki Ito, Tsutomu Miyamoto, Takeshi Uehara, Hiroyoshi Ota

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shiho Asaka *Department of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. sasaka@shinshu-u.ac.jp.ORCID http://orcid.org/0000-0003-2697-114X
Tomoyuki NakajimaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Koichi IdaDepartment of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.
Ryoichi AsakaDepartment of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.
Chinatsu KobayashiDepartment of Clinical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Masayuki ItoDepartment of Clinical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Tsutomu MiyamotoDepartment of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.
Takeshi UeharaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Hiroyoshi Ota *Department of Clinical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Shinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2020, the WHO published a new system for classifying invasive endocervical adenocarcinoma based on histological features and high-risk human papillomavirus (HPV) infection. However, immunophenotypes of each histological subtype require further investigation. We immunohistochemically analyzed 66 invasive endocervical adenocarcinomas using three cell-lineage-specific markers: claudin 18 (CLDN18) for gastric, cadherin 17 (CDH17) for intestinal, and PAX8 for Müllerian epithelial cells. We identified five immunophenotypes of endocervical adenocarcinoma: gastric (21%); intestinal (14%); gastrointestinal (11%); Müllerian (35%); and not otherwise specified (NOS) (20%). Adenocarcinomas with gastric immunophenotype, characterized by aging (p = 0.0050), infrequent HPV infection (p < 0.0001), concurrent lobular endocervical glandular hyperplasia (p = 0.0060), lymphovascular invasion (p = 0.0073), advanced clinical stage (p = 0.0001), and the poorest progression-free (p < 0.0001) and overall (p = 0.0023) survivals, were morphologically compatible with gastric-type adenocarcinoma of the WHO 2020 classification. Conversely, most adenocarcinomas with Müllerian (91%) and intestinal (89%) immunophenotypes were HPV associated and morphologically compatible with usual- or intestinal-type adenocarcinomas of the WHO 2020 classification. The morphology of adenocarcinomas with gastrointestinal immunophenotype was intermediate or mixed between those of gastric and intestinal immunophenotypes; 57% were HPV associated. Adenocarcinomas with NOS immunophenotype were mainly HPV associated (85%) and histologically poorly differentiated. Multivariate analysis revealed that gastric (p = 0.008), intestinal + gastrointestinal (p = 0.0103), and NOS (p = 0.009) immunophenotypes were independent predictors of progression-free survival. Immunophenotypes characterized by CLDN18, CDH17, and PAX8 exhibited clinicopathological relevance and may improve the diagnostic accuracy and prognostic value of conventional histological classification.

Indexed as

AdenocarcinomaPapillomavirus InfectionsUterine Cervical NeoplasmsBiomarkers, TumorCadherinsClaudinsFemaleHumansPAX8 Transcription FactorPrognosisBiomarkers, TumorCadherinsCDH17 protein, humanClaudinsCLDN18 protein, humanPAX8 protein, humanPAX8 Transcription FactorCadherin 17Claudin 18Endocervical adenocarcinomaGastric typeImmunohistochemistryIntestinal type

Identifiers

PMID34581850
OpenAlexW3203829390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.